Back to Oncology
Oncologyv2022Evidence-Based

Barcelona-Clinic Liver Cancer (BCLC) Staging Classification

Determines disease progression and appropriate treatment course for hepatocellular carcinoma (HCC) patients. The BCLC staging system integrates tumor characteristics, liver function status, and performance status to classify patients into five stages (0, A, B, C, D) with specific treatment recommendations for each stage.

Clinical Input Parameters

Range: 0 — 4
cm
Range: 0 — unlimited cm
Range: 0 — unlimited
Clinical Assessment
Awaiting Parameters
bclc stage
—Points
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The Barcelona-Clinic Liver Cancer (BCLC) Staging Classification is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within oncology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

BCLC staging is determined by a combination of: 1) Performance Status (ECOG 0-4), 2) Child-Pugh class (A/B/C), 3) Tumor characteristics (size, number, portal invasion, extrahepatic spread)

Clinical Pearls & Practice Notes

  • BCLC is the most widely used staging system for HCC as it links stage with treatment recommendations
  • Performance status is assessed using the Eastern Cooperative Oncology Group (ECOG) scale
  • Child-Pugh score assesses liver function based on bilirubin, albumin, INR, ascites, and encephalopathy
  • Portal invasion refers to macrovascular invasion visible on imaging
  • Treatment recommendations should be individualized based on local expertise and patient factors

Evidence & Literature Citations

  1. Reig M, Forner A, Rimola J, Ferrer-Fàbrega J, Burrel M, Garcia-Criado Á, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol. 2022 Mar;76(3):681-693. doi: 10.1016/j.jhep.2021.11.018.
  2. Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19(3):329-38. doi: 10.1055/s-2007-1007122.
  3. Cillo U, Vitale A, Grigoletto F, Farinati F, Brolese A, Zanus G, et al. Prospective validation of the Barcelona Clinic Liver Cancer staging system. J Hepatol. 2006 Apr;44(4):723-31. doi: 10.1016/j.jhep.2005.12.015.

Score Interpretation Ranges

0≤ pts

Very Early Stage: Single nodule <2cm, PS 0, Child-Pugh A

A≤ pts

Early Stage: Single nodule or up to 3 nodules ≤3cm, PS 0, Child-Pugh A-B

B≤ pts

Intermediate Stage: Multinodular, PS 0, Child-Pugh A-B

C≤ pts

Advanced Stage: Portal invasion or extrahepatic spread, PS 1-2, Child-Pugh A-B

D≤ pts

Terminal Stage: Any tumor burden, PS >2 or Child-Pugh C

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.